Eton Pharmaceuticals, Inc.
ETON · XNASCIK 1710340fmd_0HGKJ3Z26SAF631NDN12723H1FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 1 | – | 22 | 21 | 32 | 39 | 80 |
| Cost of revenue | – | 0 | 0 | 3 | 7 | 11 | 16 | 37 |
| Gross profit | – | 1 | (0) | 19 | 14 | 21 | 23 | 43 |
| Research and development | 6 | 12 | 14 | 6 | 4 | 3 | 3 | 8 |
| Total operating expenses | 10 | 19 | 27 | 21 | 23 | 22 | 26 | 44 |
| Operating income | (10) | (19) | (27) | (1) | (8) | (1) | (3) | (1) |
| Interest expense | – | 0 | 1 | 1 | 1 | 1 | 2 | 5 |
| Interest and investment income | 0 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | 0 | (1) | (1) | (1) | 1 | (1) | (4) |
| Income before taxes | (13) | (18) | (28) | (2) | (9) | (1) | (4) | (5) |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | (2) | (9) | (1) | (4) | (5) |
| Net income | (13) | (18) | (28) | (2) | (9) | (1) | (4) | (5) |
| Net income to common shareholders | (37) | (18) | (28) | – | – | – | – | – |